Current Status and Evaluation of Randomized Clinical Trials of Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases

Table 3

Characteristics of included RCTs on ASCVD.

Researcher	Diagnostic criteria	Sample size		Intervention		Follow-up period	Outcome
		Experiment	Control	Experiment	Control
Jianwei Gao	Guideline for diagnosis and treatment of patients with chronic stable angina, ACC/AHA/ACP–ASIM guidelines for the management of chronic stable Angina + positive result of coronary angiography or CTA or MPI+	115	117	Xinling Wan pill	Placebo	4 weeks	Reduced the amount of nitroglycerin, relieved symptoms
Junbo Ge	After AMI or PCI or CABG, epicardial coronary stenosis of ≥50% in at least one major branch	1335	1327	Shexiang Baoxin pill + optimal medical therapy	Placebo + optimal medical therapy	24 months	Reduced the occurrence of MACEs, reduced angina frequency
Ming Guo	After PCI	530	524	Xinyue capsule + standard treatment	Placebo + standard treatment	1 year	Reduced occurrence of primary endpoint event
Zhijie Shen	Guidelines for the diagnosis and treatment of unstable angina pectoris and non-ST-segment Elevation myocardial infarction + guidelines for the diagnosis and treatment of acute ST-elevation myocardial infarction	92	95	Suxiao Jiuxin pill + standard treatment	Placebo + standard treatment	12 months	Reduced the occurrence of MACEs, improved LVEF and SAQ
Wang Yonggang	After PCI + TCM syndrome differentiation	67	62	Shuangshen Tongguan capsule + standard treatment	Placebo + standard treatment	6 months	Improved LVEF and SAQ, increased k-value of the microcirculation perfusion
Danping Xu	ACC/AHA guidelines for the management of patients with chronic stable angina + TCM syndrome differentiation	59	55	Shenzhu Guanxin recipe + standard treatment	Placebo + standard treatment	90 days	Improved SAQ and daily exercise tolerance, reduced the amount of nitroglycerin
Jingen Li	Patients with SCAD	750	750	Qing-Xin-Jie-Yu Granule + standard treatment	Placebo + standard treatment	12 months	Reduced risk of the composite “hard” endpoint
Mei Zhang	Patients with noncalcified plaque	607	605	Tongxinluo capsule + standard treatment	Placebo + standard treatment	24 months	Reduced IMT and major cardiovascular events
Narayanaswamy Venketasubramanian	Ischemic stroke of intermediate severity (NIHSS) in the preceding 72h, neuroimaging findings compatible with cerebral infarction and mRS ≤1.	550	549	NeuroAiD (Danqi Piantan capsule) + standard treatment	Placebo + standard treatment	24 months	No obvious difference in rates of death and occurrence of vascular and other medical events
Darioush Savadi Oskouei	AIS involving anterior cerebral circulation	52	50	Ginkgo biloba	Placebo	4 months	Reduced NIHSS score